Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1385246.RAUCdzV04yc9iU7uD1QzgUewSbd0HxgcoSVb3hDMexUIY130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1385246.RAUCdzV04yc9iU7uD1QzgUewSbd0HxgcoSVb3hDMexUIY130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1385246.RAUCdzV04yc9iU7uD1QzgUewSbd0HxgcoSVb3hDMexUIY130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1385246.RAUCdzV04yc9iU7uD1QzgUewSbd0HxgcoSVb3hDMexUIY130_provenance.
- NP1385246.RAUCdzV04yc9iU7uD1QzgUewSbd0HxgcoSVb3hDMexUIY130_assertion description "[In a pilot study of long-term treatment, 42 such patients were randomly assigned to 6 million units of interferon alfa 2b (IFN-alpha2b) three times per week for 24 consecutive months (n = 21, 4 with cirrhosis) or to no therapy (n = 21, 3 with cirrhosis).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1385246.RAUCdzV04yc9iU7uD1QzgUewSbd0HxgcoSVb3hDMexUIY130_provenance.
- NP1385246.RAUCdzV04yc9iU7uD1QzgUewSbd0HxgcoSVb3hDMexUIY130_assertion evidence source_evidence_literature NP1385246.RAUCdzV04yc9iU7uD1QzgUewSbd0HxgcoSVb3hDMexUIY130_provenance.
- NP1385246.RAUCdzV04yc9iU7uD1QzgUewSbd0HxgcoSVb3hDMexUIY130_assertion SIO_000772 9398007 NP1385246.RAUCdzV04yc9iU7uD1QzgUewSbd0HxgcoSVb3hDMexUIY130_provenance.
- NP1385246.RAUCdzV04yc9iU7uD1QzgUewSbd0HxgcoSVb3hDMexUIY130_assertion wasDerivedFrom befree-2016 NP1385246.RAUCdzV04yc9iU7uD1QzgUewSbd0HxgcoSVb3hDMexUIY130_provenance.
- NP1385246.RAUCdzV04yc9iU7uD1QzgUewSbd0HxgcoSVb3hDMexUIY130_assertion wasGeneratedBy ECO_0000203 NP1385246.RAUCdzV04yc9iU7uD1QzgUewSbd0HxgcoSVb3hDMexUIY130_provenance.
- befree-2016 importedOn "2016-02-19" NP1385246.RAUCdzV04yc9iU7uD1QzgUewSbd0HxgcoSVb3hDMexUIY130_provenance.